FDA greenlights Bristol Myers' oral multiple myeloma drug, a first for its class
The FDA has approved Bristol Myers Squibb's oral therapy iberdomide, sold as Zenbexus, for patients with advanced multiple myeloma who have had prior treatment.
The approval marks the introduction of a new class of medicines for the blood cancer and the first U.S. approval using a more sensitive remission metric. Zenbexus will be administered together with Darzalex and dexamethasone. Bristol's chief medical officer, Cristian Massacesi, said the clearance opens the door for additional drug combinations. The decision was announced on Thursday.
Why it matters
It introduces a new treatment option for multiple myeloma and expands therapeutic possibilities for patients.
In this story
multiple myelomaiberdomideZenbexusoral treatmentnovel drug classremission measurecombination therapy
